pharma news today obesity drugs glp-1 october 2025 What's next for innovation: A primer on the race reshaping and chronic disease care GLP-1 trends 2025: real-world data,

Ipamorelin, the first selective growth hormone secretagogue European Journal of Endocrinology publishes this study on Ipamorelin, highlighting its selective action as a growth hormone secretagogue

Milara J, Lluch J, Almudever P et al (2014) Roflumilast N-oxide reverses corticosteroid resistance in neutrophils from patients with chronic obstructive pulmonary disease

GLP-1 medications may not always be effective for everyone

Center panel: Following exposure, soman-bound AChE undergoes dealkylation within approximately 2 minutes, rendering inhibition irreversible and preventing enzymatic reactivation

Every client has a consultation first to confirm the treatment is suitable for them and to discuss their goals

1 ml per day